OTTAVA Cleared for Upper Abdomen but Software Rules and Thin Data Cap Upside

FDA Authorizes Johnson & Johnson’s OTTAVA™ Robotic Surgical System

Johnson & Johnson's OTTAVA™ Robotic Surgical System received market authorization from the U.S. Food & Drug Administration (FDA) in July 2026 for use in multiple general surgery procedures within the upper abdomen, including gastric bypass, splenectomy, and hiatal hernia repair. This innovative system features robotic arms integrated directly into the operating table, significantly reducing its footprint compared to traditional systems and enabling its use in smaller operating rooms. OTTAVA™ is designed to enhance surgical efficiency, maintain procedural momentum, and elevate performance by connecting to the Polyphonic™ Digital Ecosystem, which provides integrated data, video, and AI-driven insights to surgical teams.

• The OTTAVA™ system's unique design integrates four robotic arms directly into the operating table, drastically reducing the physical footprint required in the operating room. This innovation enables robotic surgery in spaces as small as 243 square feet (23 m²), which were previously considered too small for traditional cart-mounted systems. This expanded accessibility helps hospitals optimize OR capacity and overcome infrastructure constraints, making advanced robotic-assisted procedures available to more patients.
• OTTAVA™ streamlines surgical workflows through automation capabilities, such as intelligent robotic arms that can quickly move into setup or procedure poses. It is seamlessly connected to Johnson & Johnson’s Polyphonic™ Digital Ecosystem, an open and secure platform that aggregates surgical data, video, and AI-powered insights. This integration supports preoperative planning, training, and postoperative analysis, fostering continuous learning and collaboration among healthcare teams to improve patient outcomes.
• A key differentiator of OTTAVA™ is its "twin motion" capability, allowing the integrated robotic arms and the operating table to move in synchrony. This feature enables surgeons to utilize gravity for patient repositioning and to gain optimal access to anatomy, a technique common in nonrobotic surgery but novel in robotic systems. This synchronized movement minimizes potential tissue trauma and provides surgeons with enhanced control and flexibility during complex upper abdominal procedures.

Addressing the Complexities of Upper Abdominal Surgery

Current treatment approaches for upper abdominal surgery balance efficacy against persistent infectious, technical, and durability limitations. Long-term outcomes reveal procedure-specific complication patterns and variable success of preventive or salvage strategies.

• Post-splenectomy infection and thrombotic risk remain elevated despite preventive measures: In 106 splenectomy patients, infection rate within 5 years post-splenectomy was higher in the non-traumatic vs traumatic group (42% vs 14.0%, p = 0.0040) with majority gastrointestinal (7/38) and respiratory (5/38) and surgical wound infections (3/38), and vaccinations did not appear to have a protective effect. Venous thromboembolism is common post splenectomy, with 6/85 patients developed VTE (7.06%), High BMI ≥ 30 was associated with increased risk of VTE (p = 0.007), while the use of post-operative prophylactic anticoagulation was associated with reduced risk (p = 0.005). Preserving the spleen during laparoscopic distal pancreatectomy is not associated with a lower postoperative morbidity compared to sacrificing the spleen, and tumor size ≥ 30 mm was identified as risk factor for unplanned splenectomy.

• Staple-line and anastomotic leaks in sleeve gastrectomy and gastric bypass show limited amenability to testing and endoscopic salvage: Among 55 anastomotic leaks (2.3%) identified from 2384 bariatric surgeries, 37 patients (67.3%) presented with systemic inflammatory response (SIRS leaks) and all 6 deaths (4 men and 2 women, 10.9%) occurred in the SIRS group. Endoscopic treatment of laparoscopic one anastomosis gastric bypass complications is relatively effective and safe, but anastomosis-related complications are more amenable to endoscopic treatment compared to staple line leaks, with only 1/5 with staple line leak (20%) recovering completely versus all 3 patients with anastomotic leak. In 469,588 sleeve gastrectomy cases, Staple line leakage (SLL) rate was 0.38% (1,221/ 324,264) in the IOLT group and 0.31% (453/ 145,324) in the no intraoperative leak test (NIOLT) group, with postoperative staple line leakage decreased in the NIOLT group compared with the IOLT group (OR=1.27; 95%CI 1.14 to 1.42, P=0.000), while postoperative bleeding was fewer in the IOLT group (OR 0.79; 95% CI 0.72 to 0.87, P=0.000).

• Fundoplication trades reflux control for mechanical adverse effects and dissatisfaction from new symptoms: Rates of adverse results involving dysphasia, gas-bloat syndrome, inability to belch and re-operation due to severe dysphasia were significantly higher after LNF than after laparoscopic Toupet fundoplication, with equal effectiveness on anti-reflux barrier and lower esophageal sphincter pressure. Among 1,063 patients undergoing laparoscopic fundoplication, 101 patients reported dissatisfaction, with new symptoms (gas bloat/dysphagia) as the most prominent postoperative complaint (59 %), followed by symptom recurrence (23 %), symptom persistence (4 %), and the overall experience (14 %).

• Long-term anatomical durability after concomitant hiatal hernia repair is limited by recurrence and reflux-driven reintervention: Among 111 patients who underwent sleeve gastrectomy with concomitant hiatal hernia repair, 108 were analyzed with hernia recurrence in 14 patients (13.0%), freedom from recurrence was 98.1% at 5 years and 68.9% at 10 years, and hernia size ≥ 5 cm and postoperative GERD were associated with recurrence (OR 5.0; 95% CI 1.2-20.0; P=0.035; OR 4.97; 95% CI 1.56-17.53; p = 0.008). Reintervention was required in 11 patients (10.2%), all with symptomatic GERD, while among recurrences 5 (35.7%) underwent reintervention and 9 (64.3%) were managed conservatively.

• Appendectomy outcomes depend on learning curve and intraoperative technique: Severe complications increased significantly during the learning curve, with 19 severe complications in LDC group (22,9%) versus 56 severe complications (9,3%) in OA group (p < 0.01 vs OA group), while in the LAC group 13 complications (10,4%) were found (p = 0.3 vs OA group). Copious irrigation with a minimum of 2000 mL sterile normal saline resulted in longer operation time (51.6 ± 16.1 vs. 41.5 ± 15.2 min, p <0.001) but lower postoperative intra-abdominal abscess rate (3.1% vs. 9.2%, p = 0.039), earlier anal exsufflation (25.2 ± 16.5 vs. 30.7 ± 18.1 hr, p = 0.011), and shorter hospital stay (10.2 ± 2.5 vs. 12.5 ± 2.8 days, p <0.001).

OTTAVA™'s FDA Authorization and Its Role in Surgical Care

Bariatric surgery (BS), comprising a range of various surgical procedures that modify the digestive tract favouring weight loss, is considered the most effective medical intervention to counteract severe obesity, especially in the presence of metabolic comorbidities. The Enhanced Recovery After Bariatric Surgery (ERABS) protocols include a set of recommendations that can be applied before and after BS, with the primary aim to facilitate and expedite the recovery process while enhancing the overall effectiveness of bariatric procedures. ERABS protocols include indications about preoperative fasting as well as on how to feed the patient on the day of the intervention, and how to nourish and hydrate in the days after BS, with findings that not fasting the patient before the surgery are often not correctly applied for reasons that are not evidence-based. Management of post-bariatric complications including anastomotic leaks, fistulas, and strictures relies on contrast-enhanced imaging techniques, including computed tomography (CT) and fluoroscopy, as well as endoscopic ultrasound (EUS), to identify complications and select endoscopic intervention, including endoscopic internal drainage with double pigtail plastic stents, self-expanding metal stents (SEMSs), endoscopic vacuum therapy (EVT), and EUS-guided drainage of fluid collections. Exercise training programs performed after bariatric surgery were found effective to optimize weight loss and fat mass loss and to improve physical fitness, associated with higher weight loss (mean difference: -2.4 kg, 95% CI: -4.2; -0.6, n = 12), higher fat mass loss (-2.7 kg, 95% CI: -4.5; -1.0, n = 8) and improved VO max and functional walking (standardized mean difference: 0.86, 95% CI: 0.29; 1.44, n = 6; 1.45, 95% CI: 0.32; 2.58, n = 6, respectively), with no additional effect on lean body mass loss.

Laparoscopic antireflux surgery with hiatal hernia repair consists of cruroplasty with sutures only or additional reinforcement using mesh, with closure of the diaphragmatic hiatus with crural sutures or non-absorbable polytetrafluoroethylene mesh (CruraSoft®). In a randomized, double-blind clinical trial of laparoscopic Nissen fundoplication, at 1 year the hiatal hernia had recurred in six of 64 patients (9 per cent) in the mesh group and two of 64 (3 per cent) in the suture group (P = 0·144), and at 3 years recurrence rates were 13 and 10 per cent in the mesh and suture groups respectively (P = 0·692), with reflux symptoms, use of proton pump inhibitors and oesophageal acid exposure not differing between groups, dysphagia scores decreased in both groups but more patients had dysphagia for solid food after mesh closure (P = 0·013), and quality-of-life scores comparable. In a retrospective analysis of laparoscopic hiatal hernia type II-IV repair, after a mean follow-up of 39.3 months the overall radiologic recurrence rate was 24.3%, equal in both groups [25.8% (mesh) vs 23.6% (no mesh), P = 0.331], symptomatic recurrence rate was 13.2% (16.1 vs 11.8%, P = 0.495) and reoperation rate 7.4% (9.7 vs 6.3%), with health-related quality of life improved and no serious mesh-related complications reported. Reinforcement with ProGrip™ mesh showed one recurrence in the mesh group and eight recurrences in the non-mesh group (p = 0.027) during 48 months follow-up with mean follow-up duration of 54 months (range 12-62 months), patient satisfaction significantly higher in the mesh group (p = 0.004) and more significant improvement in GERD-HRQL score (p < 0.0001), while use of vertical mesh strips (VMS) was significantly associated with fewer recurrences (OR = 0.34, p = 0.048) in a cohort with recurrence of 20.8% in 64 patients and secondary surgery in 54 patients (17.6%). A network meta-analysis of nine RCTs including 815 patients reported recurrence in 157 (19.3) patients, with rates of 21.3% for primary repair and 17.6% for mesh repair (34.7% absorbable, 12.9% non-absorbable), with no significant differences between repair techniques and confidence in evidence for all outcomes very low.

Splenectomy carries increased risk of splenic/portal vein thrombosis, with overall risk 3.3% across studies, risk factors of big spleens (i.e. myeloproliferative disorders) and hereditary hemolytic anemias, low risk in autoimmune thrombocytopenia and trauma, approximately the same incidence in laparoscopic and open splenectomy, and median time from splenectomy to symptomatic splenic vein thrombosis 8-12 days. Treatment of symptomatic splenic vein thrombosis with heparin and warfarin leads to complete resolution of thrombosis in 67%, to partial resolution in 13%, but persistent occlusion, portal hypertension or cavernoma occurred in 20%. In a ten year retrospective cohort, 6/85 patients developed VTE (7.06%), High BMI ≥ 30 was associated with increased risk of VTE (p = 0.007), while use of post-operative prophylactic anticoagulation was associated with reduced risk (p = 0.005). In patients with idiopathic non-cirrhotic portal hypertension (INCPH), transjugular intrahepatic portosystemic shunt (TIPS) and splenectomy plus esophagogastric devascularization (SED) were more effective in controlling rebleeding than endoscopic therapy + non-selective β-blockers (ET + NSBB), with rebleeding rate significantly higher in the ET + NSBB group (P < 0.01) and mortality 3.6%, 3.8% and 14.8% in the TIPS, SED and ET + NSBB groups respectively with no significant differences (P = 0.082). For laparoscopic appendectomy, intracorporeal knotting with invaginating suture versus endoloops in 152 patients (112 patients (73.7 percent) endoloops, 40 patients (26.3 per cent) knotting) showed no significant differences in overall intraoperative and postoperative complications rate and in hospital stay, median duration of operation significantly shorter with endoloop, and total cost 80 € cheaper with knotting. Endostapler devices have the lowest rate of peri-operative complications (3.56%), while endoloops and endoclips provide equivalent clinical outcomes at lower cost and operative duration was shortest with endoclip closure. For Crohn's disease requiring bowel resection, Kono-S versus conventional anastomosis in 1501 patients showed endoscopic recurrence rates of 41% vs 48% (RR 0.86, 95% CI 0.73-1.00, p = 0.05) and surgical recurrence rates of 2.7% vs 21.0% (RR 0.13, 95% CI 0.06-0.30, p < 0.001), with anastomotic leak rate 1.7% vs 4.9% (RR 0.37, 95% CI 0.19-0.74, p = 0.005) and mean operative time similar between groups.

Unpacking OTTAVA™'s Innovative Design and Clinical Benefits

Recent upper-abdominal general surgery literature spans revisional bariatric procedures, emergency small-bowel surgery, splenectomy, and hiatal and paraesophageal hernia repair. Selected studies report perioperative morbidity and mortality alongside weight loss, recurrence, and length-of-stay outcomes.

J&J's OTTAVA™: A New Blueprint for Robotic Surgical Integration

Johnson & Johnson's FDA market authorization for the OTTAVA™ Robotic Surgical System marks a pivotal moment in the evolution of surgical robotics, particularly for general surgery. This approval introduces a system uniquely designed to address some of the practical constraints that have historically limited the broader adoption of robotic platforms. By integrating robotic arms directly into the operating table, OTTAVA™ significantly reduces its physical footprint, making advanced robotic capabilities accessible to a wider array of operating rooms, including those with limited space. This design innovation directly tackles the challenge of fixed docking and large space requirements, which can be a barrier for many healthcare facilities.

A key differentiator for OTTAVA™ is its Polyphonic™ Digital Ecosystem, which promises to integrate data, video, and AI-driven insights. Research indicates that such digital ecosystems can play a crucial role in enhancing surgical training, improving workflow understanding, and supporting real-time decision-making, potentially leading to improved patient outcomes. This aligns with the broader trend of digital transformation in healthcare, where data integration and AI are increasingly leveraged to personalize treatments and optimize clinical processes. The system's ability to maintain procedural momentum and elevate performance through intelligent support could also help mitigate the steep learning curve often associated with new robotic technologies, which studies show can impact initial operating room efficiency.

However, the successful integration of OTTAVA™ into clinical practice will also need to navigate several considerations. While robotic surgery has demonstrated benefits such as reduced conversion to open surgery, shorter lengths of stay, and improved accuracy in various procedures, including emergency general surgery and lumbar revision surgery, the economic implications remain a critical factor. Studies have shown that robotic approaches can be associated with increased direct costs, supply costs, and longer operative times compared to traditional laparoscopic methods. Therefore, demonstrating superior long-term cost-effectiveness and efficiency gains that outweigh these initial investments and learning curve challenges will be crucial for widespread adoption. The generalizability, interpretability, and medicolegal accountability of AI-driven insights within the Polyphonic™ ecosystem will also require careful consideration and robust validation to ensure safe and scalable deployment. Ultimately, OTTAVA™'s entry signals a new phase in robotic surgery, emphasizing not just mechanical precision but also intelligent, integrated support for surgical teams, setting a new standard for innovation in the competitive landscape.